Mersana Therapeutics, Inc. - Special Call Transcript

Sep 17, 2020 / 12:00PM GMT
Operator

Good morning, and welcome to the Mersana Therapeutics Conference Call to Review Interim XMT-1536 Phase I Dose Expansion Data in Ovarian Cancer. (Operator Instructions)

I would now like to turn the call over to Sarah Carmody, Executive Director, Investor Relations and Corporate Communications. Please proceed.

Sarah Carmody - Mersana Therapeutics, Inc. - Executive Director of IR & Corporate Communications

Good morning, and welcome to our call. Earlier this morning, we issued a press release providing updated interim data on the ovarian cancer cohort of the expansion portion of our Phase I study of XMT-1536. This release as well as the slides we will present today are available on the Investors & Media section of our website at www.mersana.com. A replay of today's call will also be made available. After our prepared remarks, we will open the call for Q&A.

Before we begin, I'd like to mention that our call will contain forward-looking statements within the meaning of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot